Free Trial
→ July 2025 Rule Change to Impact Retirement Investors (From Premier Gold Co) (Ad)
NASDAQ:PLUR

Pluri 2/11/2025 Earnings Report

Pluri logo
$4.51 -0.06 (-1.31%)
Closing price 03:53 PM Eastern
Extended Trading
$4.51 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Pluri EPS Results

Actual EPS
-$0.53
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pluri Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pluri Announcement Details

Quarter
Date
2/11/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Pluri Earnings Headlines

Pluri (NASDAQ:PLUR) Stock Price Up 0.2% - Should You Buy?
May 29 at 3:41 AM | americanbankingnews.com
Pluri Inc. reschedules 2025 annual meeting
May 27 at 8:49 AM | investing.com
Shocking discovery could help you target payouts on weekends…
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
May 29, 2025 | WealthPress (Ad)
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
May 27 at 7:00 AM | prnewswire.com
Contrasting CARGO Therapeutics (NASDAQ:CRGX) & Pluri (NASDAQ:PLUR)
May 24, 2025 | americanbankingnews.com
Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans
May 19, 2025 | msn.com
See More Pluri Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email.

About Pluri

Pluri (NASDAQ:PLUR), a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

View Pluri Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles